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ABSTRACT
We have developed a highly sensitive, specific and
reproducible method for microRNA (miRNA) expres-
sion profiling, using the BeadArray
TM technology.
This method incorporates an enzyme-assisted spe-
cificity step, a solid-phase primer extension to dis-
tinguish between members of miRNA families. In
addition, a universal PCR is used to amplify all tar-
gets prior to array hybridization. Currently, assay
probes are designed to simultaneously analyse 735
well-annotated human miRNAs. Using this method,
highly reproducible miRNA expression profiles
were generated with 100–200ng total RNA input.
Furthermore, very similar expression profiles were
obtained with total RNA and enriched small RNA
species (R
2 0.97). The method has a 3.5–4 log
(10
5–10
9 molecules) dynamic range and is able to
detect 1.2- to 1.3-fold-differences between samples.
Expression profiles generated by this method
are highly comparable to those obtained with
RT–PCR (R
2=0.85–0.90) and direct sequencing
(R=0.87–0.89). This method, in conjunction with
the 96-sample array matrix should prove useful for
high-throughput expression profiling of miRNAs in
large numbers of tissue samples.
INTRODUCTION
MicroRNAs (miRNAs) are small ( 21nt) endogenous
non-coding RNAs that have been shown to inﬂuence the
abundance and translational eﬃciency of cognate mRNAs
(1,2). Since the discovery of the miRNA lin-4 in C. elegans
(3), many miRNAs have been identiﬁed in a wide variety
of plants and metazoans (4). According to the most recent
miRBase release (http://microrna.sanger.ac.uk/; Release
10.0: August 2007), there are over 5000 validated
miRNAs, including 528 human miRNAs (5). There are
many more predicted miRNAs that have not been
validated. It has been estimated that there are a total of
at least 800 human miRNAs (6).
miRNAs are transcribed as long precursors (pri-
miRNAs) that are processed by Drosha, resulting in an
 70-nt stem-loop structure (pre-miRNAs). The pre-
miRNAs are transported to the cytoplasm, and are further
processed by the Dicer-containing complex, resulting in
17- to 27-nt mature miRNAs. The mature miRNAs are
loaded in the RNA-induced silencing complex (RISC) that
can eﬀect gene silencing through sequence-speciﬁc base
pairing with target messenger RNAs (mRNAs), resulting
in either transcriptional/translational repression or target
breakdown. It has been shown that each miRNA can reg-
ulate the expression level of hundreds of diﬀerent
mRNAs, and between 20% and 30% of all transcripts
are regulated by miRNAs in mammalian genomes (7).
Many developmental and cellular processes have now
been found to be under critical regulation by miRNAs;
miRNA dis-regulation has been implicated in the aetiol-
ogy of diseases such as cancer (8,9), heart diseases (10) and
Parkinson’s disease (11). To further facilitate this type of
study, a tool is needed that is sensitive enough to measure
the expression levels of miRNAs speciﬁcally in small tissue
samples.
Several unique attributes of miRNAs, including their
small size, lack of polyadenylated tails, tendency to
cross-hybridize to their mRNA targets with imperfect
sequence homology, signiﬁcant sequence homology
among family members, have made them challenging to
quantify. Many methods have been developed for miRNA
proﬁling, including quantitative PCR (12), sequencing
(13–17), northern blotting (18,19) and microarray analyses
based on either direct hybridization (8,20–25) or hybridi-
zation coupled with enzymatic extension (26). While these
methods have been used successfully in a variety of stu-
dies, they still have some technical limitations. For exam-
ple, some of these methods need large amounts of starting
materials (e.g. >10mg of total RNA), while some require
enrichment of small RNA species in order to lower cross-
hybridization from mRNA, even though the enrichment
procedure itself adds variation to the measurement.
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developed a highly sensitive and speciﬁc miRNA assay.
It oﬀers unique advantages for speciﬁcity over other
sequence hybridization-based expression proﬁling plat-
forms. It can use as little as 2ng total RNA as the starting
material, signiﬁcantly lower than some existing methods.
The method has a 3.5–4 log dynamic range and is
able to detect 1.2-to 1.3-fold-diﬀerence between samples.
Furthermore, we demonstrate that robust expression
proﬁles can be generated with miRNAs isolated from
formalin-ﬁxed, paraﬃn-embedded (FFPE) tissues, which
opens up new opportunities for analyses of small RNAs
from archival human tissues.
MATERIALS AND METHODS
RNA samples
Small RNA-containing total RNAs extracted from four
cell lines [prostate adenocarcinoma (PC-3), breast adeno-
carcinoma (MCF-7), embryonic kidney (293) and cervical
Adenocarcinoma (HeLa)] and human tissues were pur-
chased from Ambion, Inc. In general, total RNAs were
used for miRNA proﬁling experiments if not otherwise
stated; for some experiments, small RNA molecules were
enriched using Invitrogen’s PureLink miRNA Isolation
Kit. FFPE samples were purchased from Biochain
Institute, Inc., and RNA was extracted using Qiagen’s
RNeasy FFPE Kit.
miRNA profiling onuniversal BeadArray platform
The method is a modiﬁcation of an assay that we devel-
oped previously for high-throughput gene expression
proﬁling, the DASL Assay (cDNA-mediated annealing,
selection, extension and ligation) (27). The miRNA
method similarly targets speciﬁc sequences with sets of
oligonucleotides that are extended, and then labelled
during PCR ampliﬁcation. As shown in Figure 1,
miRNAs were ﬁrst polyadenylated using Poly-A Polymer-
ase [5ml RNA plus 5ml polyadenylation reaction reagent
(PAS, Illumina), incubated at 378C for 60min, then heat
inactivated at 708C for 10min]. The standard miRNA
expression proﬁling assay protocol requires an input of
100–200ng of total RNA, although amounts as low as
2ng have shown good reproducibility.
The introduced poly A tail was then used as a priming
site for cDNA synthesis [8ml polyadenylation reaction
plus 8ml cDNA synthesis reagent (CSS, Illumina), incu-
bated at 428C for 60min, then heat inactivated at 708C for
10min]. As shown in Figure 1, the primer used for cDNA
synthesis was biotinylated and contained a universal PCR
primer sequence that was used later in the assay. After
cDNA synthesis, miRNAs were individually interrogated
using speciﬁc oligonucleotides. A single miRNA-speciﬁc
Oligo (MSO) was designed against each mature miRNA
sequence, which consists of three parts: at the 50-end is
another universal PCR priming site; in the middle is an
address sequence used for capturing the product on the
array; and at the 30-end is a miRNA-speciﬁc sequence. The
second universal PCR priming site is shared among all
MSO’s, and each address sequence is associated uniquely
with each of the 735 miRNA targets (see later).
The miRNA assay probes correspond to 470 well-
annotated human miRNA sequences (miRBase: http://
microrna.sanger.ac.uk/, version 9.1, February 2007
Release) and 265 miRNAs identiﬁed recently (28,29).
Assay probes were designed with a Tm of 60 8.68C and
a length of 17–21nt (average 18nt). To maximize assay
speciﬁcity, candidate probes were examined collectively to
minimize sequence similarity between probes, particularly
miRNA
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Figure 1. miRNA assay scheme. (1) Polyadenylate RNA: add multiple
A( >18 bases) to 30-ends of total RNA or puriﬁed short RNA species,
including microRNAs. (2) cDNA synthesis of microRNA: synthesize
cDNA using a biotin-labelled oligo-dT primer (blue) with a universal
sequence (red) at its 50-end. (3) Hybridize assay oligos to cDNA: attach
biotinylated cDNA to a solid phase and hybridize with a pool of
microRNA-speciﬁc oligos. (4) microRNA-speciﬁc primer extension:
extend primers using DNA polymerase. (5) Universal PCR: elute the
extended products and perform PCR with ﬂuorescently labelled univer-
sal primers. Bind double-stranded PCR products to a solid phase and
prepare the labelled, single-stranded PCR products for hybridization.
(6) Hybridize ssDNA to arrays: hybridize PCR product to capture
probes on the universal arrays.
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miRNA-speciﬁc probes is included in Supplementary
Table 1. As controls, we also designed central mismatch
probes for miRNAs hsa-let-7a, let-7c, let-7f, miR-152 and
miR-182, and 30-end mismatch probes for small nucleolar
RNAs RNU24 and RNU66 (Table 1).
The subsequent DASL assay process and array hybri-
dization were performed as described previously (27).
Brieﬂy, 15ml of the cDNA synthesis reaction was added
to 5ml of the multiplexed MSO pool (MAP, Illumina) and
30ml of a reagent containing streptavidin paramagnetic
particles (OB1, Illumina), heated to 708C, and allowed
to anneal to 408C. All 735 human miRNAs were assayed
simultaneously. After binding and washing, the annealed
MSOs were extended through the cDNA primer, forming
an ampliﬁable product. The extended oligos were eluted
from the streptavidin beads and added to a PCR reaction,
in which one of the universal primers was ﬂuorescently
labelled and the other universal primer was biotinylated.
The PCR products were captured on streptavidin para-
magnetic beads, washed and denatured to yield single-
stranded ﬂuorescent molecules to hybridize to the arrays.
The universal arrays used for ﬂuorescent reporting con-
sist of capture oligos immobilized on beads and randomly
assembled into wells etched in the ends of ﬁbre optic bun-
dles, which are arranged in a matrix to match a 96-well
plate (Sentrix Array Matrix, Illumina) (30). The identity
of each bead is determined before hybridization to the
miRNA assay product, and the same arrays are used to
report the results of similar assays employing the address
sequence technique (GoldenGate Genotyping Assay,
DASL Gene Expression Assay, GoldenGate Methylation
Assay) (30,31). Arrays were scanned on the BeadArray
Reader, and automatic image registration and intensity
extraction software was used to derive intensity data per
bead type corresponding to each miRNA (32).
Microarray dataanalysis
The array intensity data were imported into BeadStudio
v3.2 (Illumina), a software package that permits visualiza-
tion and normalization of the data. We used the ‘Average’
normalization method for all the analyses reported here
except for assay reproducibility, where, given the number
of replicates, ‘Quantile’ normalization appeared to be a
better option. The ‘Average’ normalization method com-
putes a global scaling factor that is applied to all probes
and all arrays. The ‘Quantile’ normalization method was
described previously (33). The normalized intensities and
detection P-values were exported and further analysed
using the R environment (version 2.6), in combination
with Bioconductor packages. Assessment of limit of detec-
tion, dynamic range and fold-diﬀerence detection were
performed using a combination of cell line RNA mixtures
and synthetic RNA spikes.
Real-time quantitative RT–PCR (qPCR)
qPCR analyses were performed on the ABI Prism 7900HT
sequence detection system (Applied Biosystems). RT–
PCR primers for 12 miRNAs (miR-100, 125a, 125b,
135a, 146a, 150, 17-3p, 221, 26a, 31, 93 and 328) were
purchased from ABI. Reverse transcription with
miRNA-speciﬁc primer was performed using ABI’s
TaqMan MicroRNA Reverse Transcription kit, followed
by real-time PCR protocol using miRNA-speciﬁc
TaqMan primers as suggested by the manufacturer.
Digitalgene expression (DGE) profiling
Digital gene expression proﬁling using the Genome
Analyzer sequencing platform (Illumina) was performed
for comparison and validation of miRNA assay results.
Small RNAs (size ranging from 18 to 30nt) were isolated
from 10mg total RNA on a 15% PAGE–Urea gel, and
ligated to RNA adapter-1 (50-UCGUAUGCCGUCU
UCUGCUU-30), and the ligated material was then ligated
to adapter-2 (50-GUUCAGAGUUCUACAGUCCGAC
GAUC-30). The ﬁnal ligated materials were reverse trans-
cribed with a RT-primer (50-CAAGCAGAAGACGG
CATACGA-30), and PCR ampliﬁed 15 cycles with
primer-1 (50-CAAGCAGAAGACGGCATACGA-30)
and primer-2 (50-AATGATACGGCGACCACCGACA
GGTTCAGAGTTCTACAGTCCGA-30). Please note
that primer-2 does not match adaptor-2 across the full
length. Instead, extra bases were added to the 50-end of
the adaptor sequence for a tailed PCR. The ampliﬁed
products, i.e. the small RNA libraries were loaded onto
a Cluster Station (Illumina) where they bound to comple-
mentary adapter oligos grafted onto a proprietary ﬂow
cell substrate. The Cluster Station isothermally ampliﬁed
these cDNA constructs to create clonal clusters of  1000
copies each. The resulting high-density array of template
clusters on the ﬂow cell was directly sequenced by a fully
automated Genome Analyzer (Illumina). Using a sequen-
cing-by-synthesis approach, four proprietary ﬂuorescently
labelled, reversibly terminated nucleotides were used to
Table 1. Internal single base mismatch controls and 30-end mismatch
controls
Internal single
base mismatch
control
Assay probe sequence Intensity ratio
of perfect
match/
mismatch
probes
hsa-let-7a TGAGGTAGTAGGTTGTATAG
let-7a_mis1 TGAGGTAGTAGGTTCTATAG 60
hsa-let-7c TGAGGTAGTAGGTTGTATG
let-7c_mis1 TGAGGTAGTAGGTTCTATG 37
let-7c_mis2 TGAGGTAGTAGCTTGTATG 44
hsa-let-7f TGAGGTAGTAGATTGTATAGT
let-7f_mis1 TGAGGTAGTAGATTCTATAGT 65
hsa-miR-152 TCAGTGCATGACAGAACTT
miR-152_mis1 TCAGTGCATGACACAACTT 19
hsa-miR-182 TTTGGCAATGGTAGAACTC
miR-182_mis1 TTTGGCAATGGTACAACTC 52
30-end mismatch control
RNU24 ACATTTTAAACCACCAAG
RNU24-C ACATTTTAAACCACCAAC 37
RNU24-A ACATTTTAAACCACCAAA 15
RNU24-T ACATTTTAAACCACCAAT 38
RNU66 TGAGGTGGTTCTTTCTATCC
RNU66-G TGAGGTGGTTCTTTCTATCG 12
RNU66-T TGAGGTGGTTCTTTCTATCT 21
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with an accuracy rate >99.6% per cycle. A 32-bp read
length was obtained for each cluster, and the adapter
sequence immediately ﬂanking the small RNA sequence
was removed. The resulting tag sequences were blasted
against the mature sequences of the 735 miRNAs present
on the Illumina microarray panel using Eland, an align-
ment programme within the Genome Analyzer software
suite that allows up to two mismatches. Tag sequences
matched to the 735 miRNA sequences by the Eland
algorithm were counted and used for cross-platform
comparison.
RESULTS
The miRNA assayscheme
A diagram illustrating the miRNA assay scheme is shown
in Figure 1. As discussed earlier, one MSO is designed to
assay each miRNA on the panel. A given address sequence
is uniquely associated with a miRNA sequence, which is
complementary to a capture sequence immobilized on the
universal array (see later).
The input RNA (total RNA) is ﬁrst polyadenylated and
converted to cDNA. It is worthwhile to point out that the
method gets faithful measurements of all miRNAs only if
all of them are equally well-polyadenylated. All MSOs
corresponding to the 735 miRNAs are hybridized to
their target cDNA sequences simultaneously. An allele-
speciﬁc primer extension step is then carried out: the
assay oligos are preferentially extended if their 30-bases
are complementary to their cognate sequence in the
cDNA templates. This additional enzymatic step helps
enhance the discrimination among homologous miRNA
and mRNA sequences, and provides the assay with a
second level of speciﬁcity, as compared to other methods
which only rely on DNA sequence-mediated hybridization
speciﬁcity. This enzymatic discrimination step is particu-
larly important for miRNA measurement as their small
sizes ( 21nt) greatly limit the design of optimal assay
probes. The same enzymatic biochemistry has been
widely used in genotyping of single nucleotide polymorph-
isms (31,34).
The speciﬁcally extended products are ampliﬁed using a
universal PCR which provides the assay with high sensi-
tivity. Because the PCR primers are shared among all
target sequences and amplicons are of uniform size, this
approach allows unbiased ampliﬁcation of the extended
oligo population. The labelled ampliﬁcation products are
hybridized to a universal array bearing complementary
address sequences (27,30). The signal intensity at each
address location on the array corresponds to, and reﬂects
the relative abundance of, the respective miRNAs targeted
in the original sample.
miRNA assayreproducibility
To assess assay reproducibility, we ran six RNA samples,
extracted from four cell lines (PC-3, MCF-7, 293 and
HeLa) and two tissues (liver and brain), in four to six
replicates over two operators and three 96-sample array
matrices with 200ng total RNA input (96 samples total).
We used a quantile normalization method and computed
R
2 within the same array matrix and/or operators as well
as between array matrices and/or operators. On average,
across all samples, R
2 varies from >0.97 (diﬀerent array
matrix and operators) to >0.98 (same array matrix and
same operator) (Figure 2 and Supplementary Table 2; the
microarray intensity data are provided in Supplementary
Tables 3 and 4). Highly reproducible expression proﬁles
have been generated by other groups using the same plat-
form (J.L. Schultze and J.M. Cunningham, personal com-
munications). We believe the assay reproducibility can be
further improved by increasing the number of probes
designed for each miRNA.
To assess assay performance at diﬀerent input levels, we
ran PC3 total RNA in two to four replicates at seven
diﬀerent input amounts: 2, 5, 10, 25, 50, 100 and 200ng.
We used the ‘Average’ normalization method and com-
puted R
2 to assess reproducibility for each input level.
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Figure 2. miRNA assay reproducibility. Assay intensity measured for
the 735 miRNAs in one technical replicate (replicate #1; x-axis) is
plotted against the assay intensity measured in another technical repli-
cate (replicate #2; y-axis). Two hundred nanograms total RNAs
extracted from a cell line (MCF7), fresh frozen tissue (liver) and
formalin-ﬁxed, paraﬃn-embedded (FFPE) tissue (ovarian tumor
sample) were used for each array experiment.
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correlated (R
2>0.98; Supplementary Table 5). Quite
reproducible data was obtained in technically replicated
experiments with as little as 2ng input total RNA
(R
2>0.94), although correlation between the proﬁles gen-
erated with 2 and 200ng RNA input was only modest
(R
2=0.6); this input level is 10- to 100-fold less than
that required by some other array platforms, which
makes it possible to assay small tissue samples, including
archival tissue samples (see later). Furthermore, about
90% of the miRNAs that were detected (P<0.05) with
200ng total RNA input were also detected when 2ng total
RNA was used (data not shown). Similar results were
obtained in independent studies (J.L. Schultze and J.M.
Cunningham, personal communications).
miRNA profiling withpartially degraded RNA samples
We artiﬁcially degraded the four cell-line RNAs by heat-
ing them at 908C for 30 and 150min. Proﬁles generated
with these degraded samples and the corresponding intact
samples (200ng) were compared after average normaliza-
tion; a correlation of R
2>0.96 was obtained between the
intact and the 30-min degradation samples, and a correla-
tion of R
2= 0.9 was obtained between the intact and the
150-min degradation samples. In addition, highly repro-
ducible results (R
2>0.99) have been obtained with
archived tissue samples (Figure 2). In a separate study,
we generated miRNA expression proﬁles in 130 FFPE
ovarian cancer samples (data not shown).
miRNA assay specificity
To estimate assay speciﬁcity, we designed perfect match
and central mismatch probes for miRNAs hsa_let-7a, let-
7c, let-7f, miR-152 and miR-182, and 30-end mismatch
probes for small nucleolar RNAs RNU24 and RNU66.
We calculated the intensity ratio of the perfect match
versus the mismatch probes across 24 samples. On aver-
age, we obtained a high signal/noise ratio ranging from 12
to 65 (Table 1).
In addition, we obtained high concordance (R
2>0.97)
between proﬁles generated with total RNA and low
molecular weight (LMW) RNA enriched with Invitrogen’s
PureLink miRNA Isolation Kit (Figure 3; the microarray
intensity data are provided in Supplementary Table 6).
This result suggests that the assay is very speciﬁc, in
which the presence of total RNA including mRNAs
and ribosomal RNAs (rRNAs) background did not
aﬀect overall miRNA proﬁles.
Fold-difference detection
To estimate a fold change, we used mixtures of HeLa/293
RNAs in the following percentages: 90/10, 75/25, 50/50
and 25/75% (combined input=200ng total RNA). We
chose seven miRNAs that were expressed in HeLa cells
but not in 293 cells, and then calculated the average
signal intensities for these seven targets in each mixture
and computed the fold diﬀerence in the mixtures com-
pared to the 100% HeLa RNA sample (Supplementary
Figure 1). We detected a 1.14-fold change (i.e. between
90% and 100% mixtures) for the best performing
miRNAs with a P-value of 3.59 10
 5 (Supplementary
Figure 1). On average, 1.2- to 1.3-fold diﬀerences were
detected with 95% conﬁdence.
Characterization ofsystem LOD and dynamicrange
To measure the assay dynamic range and limit of detec-
tion (LOD), we spiked eight diﬀerent amounts (ranging
from 10
3 to 10
10 molecules) of four synthetic RNAs into a
200ng total RNA background and assayed the samples in
duplicate. Using an algorithm described previously (33),
we show that our assay was able to clearly detect 10
5
molecules and started to saturate after 10
9 molecules
(Supplementary Figure 2). This corresponds to a  4 log
(10
5–10
9 molecules) dynamic range.
Quantitative RT–PCR
For comparison with another assay platform, expression
levels of 12 miRNAs were measured in the four cancer cell
lines by a stem-loop-based RT–PCR method (12); high
concordance (R
2=0.90) was obtained between the array
results and the RT–PCR results, when ‘fold-diﬀerence’
was compared (Figure 4; the original microarray and
RT–PCR data are provided in Supplementary Table 7).
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Figure 3. miRNA expression proﬁles generated with PC3 total RNA
and enriched LMW RNA. Assay intensities obtained with 200ng total
RNA (x-axis) is plotted against the intensities obtained with the corre-
sponding enriched small RNA (equivalent to 1mg of total RNA)
(y-axis).
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Figure 4. Fold-diﬀerence detected by array and RT–PCR. High con-
cordance (R
2=0.90) was obtained between the miRNA array results
and RT–PCR results. The logarithmic fold diﬀerence in abundance in
pair-wise comparisons between four cancer cell lines (PC3, 293, MCF7
and HeLa) was estimated for 12 miRNAs in both the Illumina miRNA
assay (fold diﬀerence in array intensity, x-axis) and RT–PCR (fold
diﬀerence in abundance derived from crossover threshold, y-axis).
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miRNA abundance as determined by RT–PCR was
larger than that determined by the microarray analysis.
This type of underestimating bias has been reported pre-
viously for both oligonucleotide arrays and cDNA
arrays (27).
Validation withsequencing-based digital gene
expression profiling
While the array versus RT–PCR comparison was done in
only 12 miRNAs, a more comprehensive validation of our
array method could result from a sequencing-based mea-
surement. To this end, we sequenced 8.5–10.5 million
small RNAs for each of the four cell lines described ear-
lier, using the Illumina Genome Analyzer system.
Of which, 2849000, 3207245, 4059495 and 5104527
sequence tags from 293, HeLa, PC3 and MCF7, respec-
tively aligned to the 735 mature miRNA sequences using
the Eland sequence-matching algorithm (see ‘Methods’
section and Supplementary Table 8). There was a good
correlation (R=0.78–0.83) between the absolute array
intensity and sequencing count (Figure 5A). In all these
cell lines, there were a small number of miRNAs that were
detected only by the array but not by sequencing (i.e. the
dots along the x-axis of Figure 5A), presumably the result
of limited cross-hybridization from the microarray
measurement.
Diﬀerential expression between each pair of the samples
was calculated (e.g. miRNA sequence tag counts in sample
A/miRNA sequence tag counts in sample B) and com-
pared with array results (e.g. miRNA intensity in sample
A/miRNA intensity in sample B), and an overall correla-
tion R=0.87–0.89 was obtained (Figure 5B). This corre-
lation is slightly lower than our previous results for
mRNA versus sequencing comparison (R=0.89–0.93)
(S. Luo and G. Schroth, unpublished data), which we
believe is due to the limited choice to design optimal
probes for miRNAs. However, this correlation range is
quite similar to the cross-microarray platform compari-
sons done in the MAQC study (35).
DISCUSSION
We have developed a highly sensitive and speciﬁc method
for miRNA expression proﬁling, which has a 3.5–4 log
dynamic range, over which an average 1.2-to 1.3-fold dif-
ferences in miRNA abundance can be detected with
95% conﬁdence. The method has three speciﬁc features:
(i) an enzymatic 30-end discrimination (governed by an
Figure 5. Cross-platform comparisons. (A) Correlation between the array intensity (x-axis) and sequencing count (y-axis). A natural log conversion
was used for the plot. (B) Correlation between the array intensity ratio (x-axis) and sequencing count ratio (y-axis) for each possible comparison
between four cell lines. A natural log conversion was used for the plot.
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sequence-mediated hybridization speciﬁcity; (ii) a solid-
phase cDNA selection with proven multiplexing capacity
for expression proﬁling (27,36) and (iii) a universal PCR
ampliﬁcation which renders the method highly sensitive.
Similar amplicon size with universal PCR primers has
proven to be a faithful signal ampliﬁcation method (27).
The miRNA assay method is highly sensitive; highly
reproducible miRNA expression proﬁles were generated
with 100–200ng total RNA input. Due to the high assay
speciﬁcity, this method generated very similar expression
proﬁles with total RNA and enriched low molecular
weight RNA; therefore, the puriﬁcation of small RNA
species prior to sample labelling is unnecessary. This fea-
ture will enable high-throughput miRNA analysis in a
clinical setting where only limited amounts of biopsy
material may be available.
With the current assay design, the method may oﬀer
advantages for detecting mature miRNAs more eﬀectively
than pre-miRNAs. First, the cDNA synthesis may be
more complete with short mature miRNA templates as
compared to pre-miRNAs. The extension step also
favours mature miRNAs because longer sequences will
not achieve complete extension to the same degree as
mature miRNAs under the experimental condition we
use (data not shown). More importantly, the well-known
stem-loop structure of pre-miRNAs could interfere with
cDNA synthesis and assay oligo annealing, which should
also enhance the relative detection of mature miRNAs.
Expression proﬁles generated by this method are highly
comparable to those obtained with RT–PCR and direct
sequence counting of small RNA molecules. Indeed, digi-
tal miRNA expression proﬁling (DGE) provides the most
comprehensive and rigorous cross-platform comparison:
(i) it measures all miRNAs, i.e. it is a complete and
un-biased approach and (ii) since it is sequencing-based,
it avoids any cross-hybridization issues which may exist
between array versus array and array versus RT-PCR
comparisons. Judging by this comparison, our method
appears to provide a speciﬁc and quantitative measure-
ment of miRNA abundance (Figure 5). We believe this
kind of microarray versus DGE comparison should pro-
vide an objective assessment for all diﬀerent miRNA
microarray platforms. To help facilitate this kind of
cross-platform comparison, we are currently generating
both array and sequencing data on some of the MAQC
samples as well as some standard human cell lines from
ATCC and Coriell Institute.
As new miRNA sequences are constantly discovered
and deposited in public databases, a ﬂexible array plat-
form that can swiftly handle array content updates is
highly desirable. Since our assay uses universal array read-
out, new miRNA assay probes can be easily added to
existing assay oligo pools without new array development
Figure 5. Continued.
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upgrades. Using the same design scheme, we have also
developed an assay panel targeting 380 well-annotated
mouse miRNA sequences derived from Sanger miRBase
version 9.1 (February 2007 Release) (data not shown).
We have used the method described in this paper to
proﬁle a diverse set of human embryonic stem cells,
somatic stem cells and diﬀerentiated cells (37). In addition,
the technology has been used to study a variety of human
tissue samples including archived ovarian cancer (J. Fan,
unpublished data), colon cancer (S. Thibodeau, per-
sonal communication), post-mortem brain tissues
(R. Thompson, personal communication) and peripheral
blood of patients with diseases such as chronic lymphatic
leukaemia (CLL), scheroderma, bacteremia or lung
cancer, and healthy individuals (J.L. Schultze, personal
communication). We believe, when coupled with the
96-sample array matrix platform, this method should
prove useful for high-throughput expression proﬁling of
miRNAs in large numbers of tissue samples and help to
unveil fundamental disease mechanisms.
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Supplementary Data are available at NAR Online.
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